Merestinib

CAS No. 1206799-15-6

Merestinib ( LY2801653 )

Catalog No. M17192 CAS No. 1206799-15-6

LY2801653 is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.

Purity : 95%

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 58 In Stock
5MG 96 In Stock
10MG 132 In Stock
25MG 240 In Stock
50MG 402 In Stock
100MG 573 In Stock
500MG 1197 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Merestinib
  • Note
    Research use only, not for human use.
  • Brief Description
    LY2801653 is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.
  • Description
    LY2801653 is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity. LY2801653 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing the constitutively activated c-Met protein.
  • Synonyms
    LY2801653
  • Pathway
    Cytoskeleton/Cell Adhesion Molecules
  • Target
    Kinesin
  • Recptor
    Met
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1206799-15-6
  • Formula Weight
    552.54
  • Molecular Formula
    C30H22F2N6O3
  • Purity
    95%
  • Solubility
    DMSO : ≥ 32 mg/mL. 57.92 mM
  • SMILES
    c1(=O)c(ccc(n1c1ccc(cc1)F)C)C(=O)Nc1cc(c(cc1)Oc1cc2cnn(c2cc1c1cn[nH]c1)C)F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Yan SB, Peek VL, Ajamie R, et al. Invest New Drugs. 2012 Dec 29. [Epub ahead of print]
molnova catalog
related products
  • TUG-891

    TUG-891 is a G protein-coupled receptor (GPCR) expressed in intestine, adipocytes, and pro-inflammatory macrophages that is activated by long chain free fatty acids.

  • Kif15-IN-1

    Kif15-IN-1 is a potent, selective inhibitor of KIF15 motility, can act synergistically with Eg5 inhibitors to impair cancer cell proliferation.

  • Paprotrain

    Paprotrain inhibits the ATPase activity of MKLP-2 with an IC50 of 1.35 μM and a Ki of 3.36 μM.